Finally, increased Gata2 promoter methylation, inflicted by TET2 deficiency, can be restored by demethylating 5-AZA treatment, thereby providing entry points for the development of rational targeted therapies in AML patients with these mutations. This evidence concerns the gene GATA2 and acute myeloid leukemia.